SEC Form 4 · accession 0001493152-26-029997
Oncotelic Therapeutics, Inc. · OTLC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Vuong Trieu
Officer — CHAIRMAN AND CEO · Director · 10% Owner
Period of report
Jun 22, 2026
Accepted (ET)
Jun 24, 2026 · 8:37 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0000908259
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 24, 2026 | P | 115,000 | $0.045 | A | 93,884,319 | D | |
| Common StockF1 | Jun 23, 2026 | P | 75,000 | $0.045 | A | 93,769,319 | D | |
| Common StockF1 | Jun 22, 2026 | P | 65,000 | $0.045 | A | 93,694,319 | D | |
| Common Stock | holding | — | — | — | 16,780,384 | I | By Autotelic Inc. | |
| Common Stock | holding | — | — | — | 6,872,529 | I | By spouse |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On June 22, 2026, Dr. Vuong Trieu purchased 65,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045. Further, on June 23, 2026, Dr. Vuong Trieu purchased 75,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045. Further, on June 24, 2026, Dr. Vuong Trieu purchased 115,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045.